Prescription of psychotropic drugs in paediatry: Approved indications and therapeutic perspectives;Prescription des psychotropes en pédopsychiatrie: Limites des indications officielles et perspectives thérapeutiques

Encephale

Volumn 31, Issue 4 I, 2005, Pages 477-489

  Dumortier, G ^a   Welniarz, B ^a   Sauvebois, C ^a   Medjdoub, H ^a   Friche, H ^a   Siad, N ^a   Degrassat, K ^a  

^a EPS de Ville Evrard   (France)

Author keywords

Adolescent; Child; Information; Pharmacovigilence; Psychotropic drug; Unlabelled uses

Indexed keywords

ALIMEMAZINE; ALIMEMAZINE TARTRATE; ALPRAZOLAM; AMISULPRIDE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; BUSPIRONE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOBAZAM; CLOMIPRAMINE; CLONAZEPAM; CLORAZEPATE DIPOTASSIUM; CLOZAPINE; CYAMEMAZINE; DESIPRAMINE; DIAZEPAM; FLOXYPRAL; FLUOXETINE; FLUPENTIXOL; FLUVOXAMINE; HALOPERIDOL; HYDROXYZINE; IMIPRAMINE; LITHIUM; LITHIUM CARBONATE; LITHIUM GLUCONATE; LORAZEPAM; LOXAPINE SUCCINATE; LUDIOMOL; MAPROTILINE; MEPROBAMATE; METHYLPHENIDATE; MIANSERIN; MILNACIPRAN; NORSET; NORZINAN; OLANZAPINE; OXAZEPAM; PAROXETINE; PERICIAZINE; PERTOFAN; PIMOZIDE; PIPAMPERONE; PIPOTIAZINE; PRAZEPAM; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULPIRIDE; THIORIDAZINE; TIANEPTINE; TIAPRIDE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; VILOXAZINE; ZOLPIDEM TARTRATE; ZOPICLONE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ANXIETY DISORDER; AUTISM; BEHAVIOR DISORDER; CHILDHOOD DISEASE; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EDUCATION PROGRAM; FRANCE; GOOD CLINICAL PRACTICE; HUMAN; HYPERACTIVITY; INSOMNIA; INTELLIGENCE QUOTIENT; META ANALYSIS; MOOD DISORDER; OBSESSIVE COMPULSIVE DISORDER; PATIENT COMPLIANCE; PATIENT MONITORING; PRESCRIPTION; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RELATIVE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNITED STATES;

EID: 27244454274     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0013-7006(05)82409-1     Document Type: Article

References (85)

1. ALDERMAN J, WOLKOW R, CHUNG M et al. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry 1998; 37 (4): 386-94.
2. AMAN MG, MARKS RE, TURBOTT SH et al. Methylphenidate and thioridazine in the treatment of intellectually subaverage children: effects on cognitive-motor performance. J Am Acad Child Adolesc Psychiatry 1991; 30 (5): 816-24.
3. AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY 2002. American Academy of Child and Adolescent Psychiatry Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatr 2001; 40 (Suppl 7): 4S-23S.
4. ANDERSON LT, CAMPBELL M, GREGA DM et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984; 141 (10): 1195-202.
5. ANONYME. Sertraline: new indication. May help children with obsessive-compulsive disorder. Prescrire Int 2002; 11 (59): 69-72.
6. ARNOLD LE, AMAN MG, MARTIN A et al. Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology. J Autism Dev Disord 2000; 30 (2): 99-111.
7. BALDESSARINI RJ, TARAZI FI. Brain dopamine receptors: a primer on their current status, basic and clinical. Harv Rev Psychiatry 1996; 3 (6): 301-25.
8. BEIDEL DC, FERRELL C, ALFANO CA et al. The treatment of childhood social anxiety disorder. Psychiatr Clin North Am 2001; 24 (4): 831-46.
9. BERGER M, RIGAUD C. Le point de vue du psychothérapeute sur la prescription de psychotropes chez l'enfant de moins de 12 ans. Neuropsychiatr Enf Adolesc 2001; 49: 108-12.
10. BIEDERMAN J, BALDESSARINI RJ, WRIGHT V et al. A double-blind placebo controlled study of desipramine in the treatment ADD: II. Serum drug levels and cardiovascular findings. J Am Acad Child Adolesc Psychiatry 1989; 28 (6): 903-11.
11. BIEDERMAN J, THISTED RA, GREENHILL LL et al. Estimation of the association between desipramine and the risk for sudden death in 5 to 14 year-old children. J Clin Psychiatry 1995; 56 (3): 87-93.
12. BIGLIANI V, PILOWSKY LS. In vivo neuropharmacology of schizophrenia. Br J Psychiatry 1999; 38: 23-33.
13. BLACK B, UHDE TW. Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1994; 33 (7): 1000-6.
14. BRUUN RD, BUDMAN CL. Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry 1996; 57 (1): 29-31.
15. CAMPBELL M, ADAMS PB, SMALL AM et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1995; 34 (4): 445-53.
16. CAMPBELL M, KAFANTARIS V, CUEVA JE. An update on the use of lithium carbonate in aggressive children and adolescents with conduct disorder. Psychopharmacol Bull 1995; 31 (1): 93-102.
17. CHAN RT, REY JM, HAZELL PL. Clinical practice guidelines for depression in young people: are the treatment recommendations outdated? Med J Aust 2002; 177 (8): 448-51.
18. CHEER SM, FIGGITT DP. Spotlight on fluvoxamine in anxiety disorders in children and adolescents. CNS Drugs 2002; 16 (2): 139-44.
19. CLERVOY P, CORCOS M, BOCHEREAU D. Les traitements thymorégulateurs dans la psychose maniaco-dépressive chez l'adolescent. Perspect Psy 1999; 38 (1): 62-8.
20. CONDAT A. MOUREN-SIMEONI MC. Inhibiteurs de la recapture de la sérotonine et dépression chez l'enfant et l'adolescent. Encephale 2000, XXVI: 53-60.
21. CORCOS M, CLERVOY P, JEAMMET P. Presentations and diagnostic criteria of schizophrenia. Rev Prat 2002; 52 (11): 1183-90.
22. CUCHERAT M. Méta-analyse des essais thérapeutiques. Paris: Massen, Coll Évaluation et Statistique, 1997.
23. CUEVA JE, OVERALL JE, SMALL AM et al. Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1996; 35 (4): 480-90.
24. DEBERDT R. Oxazepam in the treatment of anxiety in children and the elderly. Acta Psychiatr Scand Suppl 1978; 274: 104-10.
25. DSM IV, Manuel diagnostique et stastistique des troubles mentaux. Paris: Masson, 1996.
26. DUGAS M, ZARIFIAN E, LE HEUZEY MF et al. Surveillance des taux plasmatiques de psychotropes chez l'enfant I - Taux plasmatiques d'halopéridol. Nouv Presse Med 1982; 11 (29): 2201-4.
27. DUMORTIER G, COHEN DE MELO P, CELIS C et al. Interactions pharmacocinétiques de la clozapine. Inf Psychiatr 1996; 8: 832-6.
28. DYER KS, WOOLF AD. Use of phenothiazines as sedatives in children: what are the risks? Drug Saf 1999; 21 (2): 81-90.
29. EMSLIE GJ, RUSH AJ, WEINBERG WA et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54 (11): 1031-7.
30. FANKHAUSER MP, KARUMANCHI VC, GERMAN ML et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992; 53 (3): 77-82.
31. FERRERI M, ROUILLON F, NUSS P et al. What is the schizophrenic patients' level of information about their disease and their treatment? Encephale 2000; 26 (Spec n° 1): 15-22.
32. FERRERI M, ROUILLON F, NUSS P et al. What information do patients with schizophrenia have about their illness and treatment? Encephale 2000; 26 (5): 30-8.
33. FILIPEK PA, ACCARDO PJ, ASHWAL S et al. Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology 2000; 55 (4): 468-79.
34. FINDLING RL, McNAMARA NK, GRACIOUS BL. Paediatric uses of atypical antipsychotics. Expert Opin Pharmacother 2000; 1 (5): 935-45.
35. FISMAN S, STEELE M. Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 1996; 6 (3): 177-90.
36. GELLER B, COOPER TB, SUN K et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 1998; 37 (2): 171-8.
37. GILLBERG C. Typical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 2000; 9 (Suppl 1): 12-8.
38. GORDON CT, STATE RC, NELSON JE et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993; 50 (6): 441-7.
39. GUTGESELL H, ATKINS D, BARST R et al. AHA Scientific statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry 1999; 38(8): 1047-50.
40. 2a receptors. Br J Psychiatry 1999; 38: 12-22.
41. HAZELL P, O'CONNELL D, HEATHCOTE D et al. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002; 2: CD002317.
42. KALACHNIK JE, HANZEL TE, SEVENICH R et al. Benzodiazepine behavioral side effects: review and implications for individuals with mental retardation. Am J Ment Retard 2002; 107 (5): 376-410.
43. KELLER MB, RYAN ND, STROBER M et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40 (7): 762-72.
44. KOSSOFF EH, SINGER HS. Tourette syndrome: clinical characteristics and current management strategies. Paediatr Drugs 2001; 3 (5): 355-63.
45. KOWATCH RA, CARMODY TJ, EMSLIE GJ et al. Prediction of response to fluoxetine and placebo in children and adolescents with major depression: a hypothesis generating study. J Affect Disord 1999; 54 (3): 269-76.
46. KOWATCH RA, SUPPES T, CARMODY TJ et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2000; 39 (6): 713-20.
47. KUMRA S, FRAZIER JA, JACOBSEN LK et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996; 53 (12): 1090-7.
48. KUTCHER S. Practical child and adolescent psychopharmacology. Cambridge: University Press, 2002.
49. L'EILDÉ-BALCON C, LEMONNIER E, CHAMOUX F et al. Les traitements pharmacologiques de la dépression chez l'enfant et l'adolescent. J Pharm Clin 2001; 20: 171-7.
50. LEONARD HL, MEYER MC, SWEDO SE et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry 1995; 34 (11): 1460-8.
51. LOMBROSO PJ, SCAHILL L, KING RA et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 1995; 34 (9): 1147-52.
52. MALONE RP, CATER J, SHEIKH RM et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001; 40 (8): 887-94.
53. MANEETON N, SRISURAPANONT M. Tricyclic antidepressants for depressive disorders in children and adolescents: a meta-analysis of randomized-controlled trials. J Med Assoc Thai 2000; 83 (11): 1367-74.
54. MARCH JS, BIEDERMAN J, WOLKOW R et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 1998; 280 (20): 1752-6.
55. MASSARI B. La prescription des psychotropes en psychiatrie de l'enfant. Neuropsychiatr Enf 1984; 32 (9): 433-41.
56. McCRACKEN JT, McGOUGH J, SHAH B et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347 (5): 314-21.
57. McDOUGLE CJ, HOLMES JP, BRONSON MR et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997; 36 (5): 685-93.
58. MICHAEL KD, CROWLEY SL. How effective are treatments for child and adolescent depression? A meta-analytic review. Clin Psychol Rev 2002; 22 (2): 247-69.
59. MURPHY TK, BENGTSON MA, TAN JY et al. Selective serotonin reuptake in the treatment of paediatric anxiety. Int Clin Psychopharmacol 2000; 15 (Suppl 2): S47-S63.
60. NASH LT, HACK S. The pharmacological treatment of anxiety disorders in children and adolescents. Expert Opin Pharmacother 2002; 3 (5): 555-71.
61. OLFSON M, MARCUS SC, WEISSMAN MM et al. National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 2002; 41 (5): 514-21.
62. PERRY R, CAMPBELL M, ADAMS P et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 1989; 28 (1): 87-92.
63. PERRY R, PATAKI C, MUNOZ-SILVA DM et al. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol 1997; 7 (3): 167-79.
64. PETTI TA, FISH B, SHAPIRO T et al. Effects of chlordiazepoxide in disturbed children: a pilot study. J Clin Psychopharmacol 1982; 2 (4): 270-3.
65. PISCITELLI SC, FRAZIER JA, McKENNA K et al. Plasmaclozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. J Clin Psychiatry 1994; 55 (Suppl B): 94-7.
66. PHYSICIANS' DESK REFERENCE, MEDICAL ECONOMICS. Montvale, NJ, USA: Thomson Healthcare, 2002.
67. REMINGTON G, SLOMAN L, KONSTANTAREAS M et al. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 2001; 21 (4): 440-4.
68. REMSCHMIDT H, HENNIGHAUSEN K, CLEMENT HW et al. Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 2000; 9 (Suppl 1): 19-29.
69. REMSCHMIDT H. Early-onset schizophrenia as a progressive-deteriorating developmental disorder: evidence from child psychiatry. J Neural Transm 2002; 109 (1): 101-17.
70. RESEARCH UNIT ON PEDIATRIC PSYCHOPHARMACOLOGY ANXIETY STUDY GROUP, 2001. Anonyme Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med 2001; 344 (17): 1279-85.
71. RIDDLE MA, REEVE EA, YARYURA-TOBIAS JA et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001; 40 (2): 222-9.
72. ROCHET T, REVOL O, MAILLET J et al. Les psychotropes en psychiatrie de l'enfant et de l'adolescent. Ann Pediatr 1993; 40 (9): 553-63.
73. RYNN MA, SIQUELAND L, RICKELS K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001; 158 (12): 2008-14.
74. SANCHEZ L, HAGINO O, WELLER E et al. Bipolarity in children. Psychiatr Clin North Am 1999; 22 (3): 629-48.
75. SCAHILL L, McCRACKEN J, McDOUGLE CJ et al. Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. J Child Adolesc Psychopharmacol 2001; 11 (4): 377-88.
76. STEIN DJ. Obsessive-compulsive disorder. Lancet 2002; 360 (9330): 397-405.
77. STEINGARD RJ, ZIMNITZKY B, DEMASO DR et al. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 1997; 7 (1): 9-15.
78. STEINGARD R, BIEDERMAN J, SPENCER T et al. Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 1993; 32 (2): 350-3.
79. STIGLER KA, POTENZA MN, McDOUGLE CJ. Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs 2001; 3 (12): 927-42.
80. THÉVENOT JP, BOUDART Y. Le psychiatre d'enfant face à la prescription de médicament: Résultat de l'enquête nationale. Inform Psychiatr 2000; 76 (3): 267-72.
81. VIDAL, Édition 2003.
82. VOLKMAR F, COOK E JR, POMEROY J et al. Summary of the practice parameters for the assessment and treatment of children, adolescents and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 1999; 38 (12): 1611-6.
83. WAGNER KD. Generalized anxiety disorder in children and adolescents. Psychiatr Clin North Am 2001; 24 (1): 139-53.
84. WERRY JS, BIEDERMAN J, THISTED R et al. Resolved: cardiac arrhythmias make desipramine an unacceptable choice in children. J Am Acad Child Adolesc Psychiatry 1995; 34 (9): 1239-45.
85. WILENS TE, BIEDERMAN J, MARCH JS et al. Absence of cardiovascular adverse effects of sertraline in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999; 38 (5): 573-7.